- Piulats JM, Espinosa E, Merino LD, Varela M, Carrion LA, Martin Algarra S, Castro RL, Curiel T, Rodriguez Abreu D, Redrado M, Goma M, Rullan AJ, Gonzalez AC, Berrocal Jaime A. Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586-598. doi:10.1200/JCO.20.00550. IF:44,54.
- Guigay J, Auperin A, Fayette J, Saada Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus Clement C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R, G, A, TTCC, UniCancer Head Neck GRP. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-475. doi:10.1016/S1470-2045(20)30755-5. IF:41,32.
- Oliva M, Chepeha D, Araujo DV, Diaz Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, Hansen AR, Hope A, Goldstein D, Weinreb I, Smith S, Perez Ordonez B, Irish J, Torti D, Bruce JP, Wang B, Fortuna A, Pugh TJ, Der Torossian H, Shazer R, Attanasio N, Au QY, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu LL. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021;9(10):doi:10.1136/jitc-2021-003476. IF:13,75.
- Oliva M, Schneeberger PHH, Rey V, Cho M, Taylor R, Hansen AR, Taylor K, Hosni A, Bayley A, Hope AJ, Bratman SV, Ringash J, Singh S, Weinreb I, Perez Ordoñez B, Chepeha D, Waldron J, Xu W, Guttman D, Siu LL, Coburn B, Spreafico A. Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). Br. J. Cancer. 2021;124(9):1543-1551. doi:10.1038/s41416-020-01253-1. IF:7,64.
- Arribas L, Plana M, Taberna M, Sospedra M, Vilarino N, Oliva M, Pallares N, Tampan A, Del Rio LM, Mesia R, Baracos V. Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Oncol. 2021;11699668-699668. doi:10.3389/fonc.2021.699668. IF:6,24.